Stablepharma and BulBio establish thermostability of StablevaX™-Td Vaccine After Exposure to +45℃ for 12 monthsStablepharma is delighted to announce that we are fully funded on Crowdcube after just a few weeks, reaching and exceeding our target of £3m !
A child dying every 20 seconds is an unacceptable statistic. Stablepharma is The Fridge-Free Vaccine Company, committed to launching the world’s first fridge-free vaccines, eliminating the need for the cold chain and enabling stockpiling anywhere in the world.
Our novel patented StablevaX™ technology is designed to dramatically enhance the performance of existing and new vaccines, thermally stabilise and deliver a wide range of vaccines without the requirement for refrigeration.
Stablepharma’s fridge-free vaccines can help expand access to patients and increase the success of immunisation programmes.
Latest Press Coverage on StablevaX™
The WHO state that roughly 50% of vaccines are wasted due mostly to failures in the cold chain.
Stablepharma aims to ensure that all vaccines can be removed from the refrigerated cold chain and stored for months or even years at room temperature.
StablevaX™ is a patented product that aims for enhanced thermostability, following WHO protocols
StablevaX™ technology aims to eliminate the need for refrigeration
StablevaX™ technology is designed with the aim of administering to patients without any change to current practice
Our white paper
StablevaX™ - a complementary technology for COVID-19 vaccines
In light of the ongoing Covid-19 pandemic, the challenge of equitable and efficient vaccine delivery has never been starker. Stablepharma believes that StablevaX™ could be a crucial complementary technology to currently available Covid-19 vaccines, especially those using mRNA-based approaches.